Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T20:07:06.837Z.
Calculation as of: 2026-10-06T20:07:06.837Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: dc00e8cb63dba40c56ed5fb80588e73c180b52fe93b8081d2416c5f575d95e45
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Insight Molecular Diagnostics Inc.
Market Cap
$109.14M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$110.30M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$107.09M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$106.98M
Price/FCF Ratio
N/A
TTM Avg
23.61
3Y Avg
13.61
5Y Avg
10.78
Market Cap
$106.96M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.57M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $109.14M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $110.30M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $107.17M | N/A | N/A | N/A | N/A |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.09M | N/A | N/A | N/A | N/A |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.98M | N/A | 23.61 | 13.61 | 10.78 |
| Outlook Therapeutics, Inc. (OTLK)vs › | $106.96M | N/A | N/A | N/A | N/A |
| Vivani Medical, Inc. (VANI)vs › | $106.93M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $106.52M | N/A | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | N/A | N/A | N/A | N/A |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.94M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
